Monica Fung
Infectious Disease · San Francisco, CANPI 1871931584
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $600 of the $600 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Takeda Pharmaceuticals U.S.A., Inc..
Across 1 payment — averaging $600.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$600
Across 4 payments — averaging $170,561 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$643K
- Scynexis, Inc.$29K
- Modernatx, Inc.$10K
What the payments were for
- Consulting fees$600100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $600 |
How this compares
$600 in reported general payments places this provider in the 60th percentile of 856 infectious disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 37 | $155,015 |
| CresembaIsavuconazonium Sulfate | 11 | $74,991 |
| TivicayDolutegravir Sodium | 27 | $62,664 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 14 | $48,387 |
| DescovyEmtricitabine/Tenofov Alafenam | 18 | $43,452 |
| EdurantRilpivirine Hcl | 15 | $22,964 |
| Darunavir | 11 | $18,189 |
| Daptomycin | 22 | $6,796 |
| EliquisApixaban | 11 | $6,232 |
| JanuviaSitagliptin Phosphate | 14 | $5,827 |
| Entecavir | 12 | $3,752 |
| Oxycodone Hcl | 16 | $528 |
| ValacyclovirValacyclovir Hcl | 12 | $250 |
| Amoxicillin | 15 | $223 |
| Omeprazole | 25 | $180 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in San Francisco
- Shawn HasslerSan Francisco$433K
- Abhijit LimayeSan Francisco$152K
- Joel PalefskySan Francisco$68K
- Monica GandhiSan Francisco$60K
- Claire PomeroySacramento$2.6M
- Javeed SiddiquiRoseville$1.5M
- George SakoulasSan Diego$902K
- Arthur JengSylmar$766K
- James McKinnellTorrance$762K
- Jay GladsteinLos Angeles$657K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.